“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

07 May 2019
Pharma

Visiongain has launched a new pharma report mRNA Vaccines and Therapeutics Market Report: Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy.

mRNA-based drugs have emerged as a highly attractive new class of biologics that encodes any protein of interest directly in vivo. The last two decades have been crucial in generating interest in various RNA based technologies. Clinical and preclinical trials in the field have led to positive responses facilitating increasing funding and investment by major pharmaceutical and biopharmaceutical companies. Clinical trials have proven that mRNA vaccines provide long lasting immune responses and are safe in animal and human models.

The lead analyst of the report commented "The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

Effective and safe delivery remains a major challenge despite the potential of RNA therapy. High cost of development and stringent process of regulatory approvals might also restrain the mRNA vaccines and therapeutics market."

Leading companies featured in the report include Argos Therapeutics, Inc., BioNTech AG. CureVac AG, eTheRNA Immunotherapies, ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamo Therapeutics, Inc., Tiba Biotech, Translate Bio, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Rare Diseases Market Report 2021-2031

As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.

02 March 2021

Read

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

26 February 2021

Read

Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031

The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.

22 February 2021

Read

Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031

The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.

22 February 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever